This protocol targets neurologically stable patients with chronic subdural hematoma (cSDH) who present with significant clinical symptoms and imaging findings that meet established thresholds for active intervention.
Neurologically stable cSDH with significant symptoms, where imaging demonstrates an initial hematoma thickness greater than 10 mm or a brain midline shift greater than 5 mm — a profile typically considered for active management.
For recurrent cases in which primary management has not achieved resolution, an antiangiogenic pharmacological strategy represents one available therapeutic avenue.
DOI: 10.1161/STROKEAHA.123.044129
Patients with significant symptoms are typically associated with an initial hematoma thickness >10 mm or a midline shift >5 mm, and they are typically considered for surgical treatment.
There have been initial reports of using the antiangiogenic pharmacological agent bevacizumab to treat recurrent cSDH following failed primary attempts, and this may open a novel therapeutic target in the future.
View source ↗